<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Biomarin Pharmaceutical Inc — News on 6ix</title>
<link>https://6ix.com/company/biomarin-pharmaceutical-inc</link>
<description>Latest news and press releases for Biomarin Pharmaceutical Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 12:44:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/biomarin-pharmaceutical-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68354e7178dffbe2df0e65d4.webp</url>
<title>Biomarin Pharmaceutical Inc</title>
<link>https://6ix.com/company/biomarin-pharmaceutical-inc</link>
</image>
<item>
<title>BioMarin Completes Acquisition of Amicus Therapeutics</title>
<link>https://6ix.com/company/biomarin-pharmaceutical-inc/news/biomarin-completes-acquisition-of-amicus-therapeutics</link>
<guid isPermaLink="true">https://6ix.com/company/biomarin-pharmaceutical-inc/news/biomarin-completes-acquisition-of-amicus-therapeutics</guid>
<pubDate>Mon, 27 Apr 2026 12:44:00 GMT</pubDate>
<description>BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today that it completed the previously announced agreement to acquire Amicus Therapeutics for $14.50 per share in an all-cash transaction for a total equity value of approximately $4.8 billion. The acquisition will strengthen BioMarin's commercial portfolio, adding two new treatments to the company's existing portfolio of medicines that target lysosomal storage diseases: Galafold® (migalastat), the first oral treatment for Fabry disease, and Pombi</description>
</item>
<item>
<title>BioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET</title>
<link>https://6ix.com/company/biomarin-pharmaceutical-inc/news/biomarin-to-host-first-quarter-2026-financial-results-conference-call-and-webcast-on-monday-may-4-2026-at-430pm-et</link>
<guid isPermaLink="true">https://6ix.com/company/biomarin-pharmaceutical-inc/news/biomarin-to-host-first-quarter-2026-financial-results-conference-call-and-webcast-on-monday-may-4-2026-at-430pm-et</guid>
<pubDate>Mon, 27 Apr 2026 11:30:00 GMT</pubDate>
<description>BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, May 4, 2026, at 4:30 p.m. ET to discuss first quarter 2026 financial results and provide a general business update.</description>
</item>
<item>
<title>BioMarin Announces Board Leadership Transition</title>
<link>https://6ix.com/company/biomarin-pharmaceutical-inc/news/biomarin-announces-board-leadership-transition</link>
<guid isPermaLink="true">https://6ix.com/company/biomarin-pharmaceutical-inc/news/biomarin-announces-board-leadership-transition</guid>
<pubDate>Tue, 21 Apr 2026 20:23:00 GMT</pubDate>
<description>BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today that the Board of Directors has appointed Ian T. Clark as Chair of the Board, subject to his election at the company's Annual Meeting of Stockholders on June 2, 2026. Mr. Clark will succeed Richard A. Meier, who is retiring after two decades on the Board, and the appointment will become effective immediately following the Annual Meeting.</description>
</item>
<item>
<title>Roctavian (BioMarin Pharmaceutical) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F</title>
<link>https://6ix.com/company/biomarin-pharmaceutical-inc/news/roctavian-biomarin-pharmaceutical-market-research-report-2026-epidemiology-pipeline-analysis-trends-strategies-and-forecasts-2020-2025-2025-2030f-2035f</link>
<guid isPermaLink="true">https://6ix.com/company/biomarin-pharmaceutical-inc/news/roctavian-biomarin-pharmaceutical-market-research-report-2026-epidemiology-pipeline-analysis-trends-strategies-and-forecasts-2020-2025-2025-2030f-2035f</guid>
<pubDate>Fri, 13 Mar 2026 16:35:00 GMT</pubDate>
<description>Key market opportunities include advancements in gene delivery, growing demand for durable hemophilia treatments, increased healthcare investments, and expanding personalized medicine frameworks. The rise in hemophilia prevalence and the shift towards one-time gene therapies also provide significant growth prospects.Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The "Roctavian Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's</description>
</item>
<item>
<title>BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting</title>
<link>https://6ix.com/company/biomarin-pharmaceutical-inc/news/biomarin-presents-new-data-on-the-positive-impact-of-early-treatment-with-voxzogor-vosoritide-on-proportionality-and-arm-span-in-children-with-achondroplasia-at-the-2026-american-college-of-medical-genetics-and-genomics-acmg-annual-clinical-genetics-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/biomarin-pharmaceutical-inc/news/biomarin-presents-new-data-on-the-positive-impact-of-early-treatment-with-voxzogor-vosoritide-on-proportionality-and-arm-span-in-children-with-achondroplasia-at-the-2026-american-college-of-medical-genetics-and-genomics-acmg-annual-clinical-genetics-meeting</guid>
<pubDate>Thu, 12 Mar 2026 13:05:00 GMT</pubDate>
<description>BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced positive new data from studies of VOXZOGO® (vosoritide) in children with achondroplasia in ongoing clinical trials and real-world studies. The latest findings reinforce the importance of early treatment and the well-known, established efficacy and safety of VOXZOGO. The data will be presented at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Baltimore.</description>
</item>
<item>
<title>BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Geneti...</title>
<link>https://6ix.com/company/biomarin-pharmaceutical-inc/news/biomarin-presents-new-data-on-the-positive-impact-of-early-treatment-with-voxzogor-vosoritide-on-proportionality-and-arm-span-in-children-with-achondroplasia-at-the-2026-american-college-of-medical-genetics-and-genomics-acmg-annual-clinical-geneti-4</link>
<guid isPermaLink="true">https://6ix.com/company/biomarin-pharmaceutical-inc/news/biomarin-presents-new-data-on-the-positive-impact-of-early-treatment-with-voxzogor-vosoritide-on-proportionality-and-arm-span-in-children-with-achondroplasia-at-the-2026-american-college-of-medical-genetics-and-genomics-acmg-annual-clinical-geneti-4</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with</description>
</item>
<item>
<title>Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer</title>
<link>https://6ix.com/company/biomarin-pharmaceutical-inc/news/absci-strengthens-clinical-leadership-with-appointment-of-ransi-somaratne-md-facc-mba-as-chief-medical-officer-1</link>
<guid isPermaLink="true">https://6ix.com/company/biomarin-pharmaceutical-inc/news/absci-strengthens-clinical-leadership-with-appointment-of-ransi-somaratne-md-facc-mba-as-chief-medical-officer-1</guid>
<pubDate>Tue, 03 Mar 2026 13:00:00 GMT</pubDate>
<description>Former Vertex executive to spearhead the clinical development of Absci’s expanding AI-designed therapeutics pipeline Chief Innovation Officer Andreas Busch to retire March 31, 2026 and will continue to co-chair Absci’s Scientific Advisory Board VANCOUVER, Wash. and NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the appointment of Ransi Somara</description>
</item>
<item>
<title>U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU)</title>
<link>https://6ix.com/company/biomarin-pharmaceutical-inc/news/us-food-and-drug-administration-approves-biomarins-palynziqr-pegvaliase-pqpz-for-adolescents-12-years-of-age-and-older-with-phenylketonuria-pku</link>
<guid isPermaLink="true">https://6ix.com/company/biomarin-pharmaceutical-inc/news/us-food-and-drug-administration-approves-biomarins-palynziqr-pegvaliase-pqpz-for-adolescents-12-years-of-age-and-older-with-phenylketonuria-pku</guid>
<pubDate>Fri, 27 Feb 2026 05:00:00 GMT</pubDate>
<description>Treatment with PALYNZIQ led to statistically significant blood phenylalanine (Phe) lowering compared to diet alone in pivotal Phase 3 PEGASUS studyPALYNZIQ is</description>
</item>
<item>
<title>BioMarin to Participate in Four Upcoming Investor Conferences in March</title>
<link>https://6ix.com/company/biomarin-pharmaceutical-inc/news/biomarin-to-participate-in-four-upcoming-investor-conferences-in-march</link>
<guid isPermaLink="true">https://6ix.com/company/biomarin-pharmaceutical-inc/news/biomarin-to-participate-in-four-upcoming-investor-conferences-in-march</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>TD Cowen 46th Annual Health Care Conference on Wednesday, March 4, 2026 Leerink 2026 Global Healthcare Conference on Monday, March 9, 2026Jefferies 2026</description>
</item>
<item>
<title>BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results</title>
<link>https://6ix.com/company/biomarin-pharmaceutical-inc/news/biomarin-reports-fourth-quarter-and-full-year-2025-financial-and-operating-results</link>
<guid isPermaLink="true">https://6ix.com/company/biomarin-pharmaceutical-inc/news/biomarin-reports-fourth-quarter-and-full-year-2025-financial-and-operating-results</guid>
<pubDate>Mon, 23 Feb 2026 21:05:00 GMT</pubDate>
<description>BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the fourth quarter and full year ended December 31, 2025.</description>
</item>
<item>
<title>BioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET</title>
<link>https://6ix.com/company/biomarin-pharmaceutical-inc/news/biomarin-host-fourth-quarter-full-140000164</link>
<guid isPermaLink="true">https://6ix.com/company/biomarin-pharmaceutical-inc/news/biomarin-host-fourth-quarter-full-140000164</guid>
<pubDate>Tue, 17 Feb 2026 14:00:00 GMT</pubDate>
<description>BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, February 23, 2026, at 4:30 p.m. ET to discuss fourth quarter and full-year 2025 financial results and provide a general business update.</description>
</item>
<item>
<title>BioMarin Announces Closing of Private Offering of Senior Notes</title>
<link>https://6ix.com/company/biomarin-pharmaceutical-inc/news/biomarin-announces-closing-private-offering-210500369</link>
<guid isPermaLink="true">https://6ix.com/company/biomarin-pharmaceutical-inc/news/biomarin-announces-closing-private-offering-210500369</guid>
<pubDate>Thu, 12 Feb 2026 21:05:00 GMT</pubDate>
<description>BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it closed its previously announced offering of $850 million of 5.500% senior unsecured notes due 2034 (the "Notes"). The issue price of the Notes is 100.000%.</description>
</item>
<item>
<title>BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility</title>
<link>https://6ix.com/company/biomarin-pharmaceutical-inc/news/biomarin-announces-pricing-private-offering-210500167</link>
<guid isPermaLink="true">https://6ix.com/company/biomarin-pharmaceutical-inc/news/biomarin-announces-pricing-private-offering-210500167</guid>
<pubDate>Thu, 29 Jan 2026 21:05:00 GMT</pubDate>
<description>BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it priced its previously announced offering of $850 million of 5.500% senior unsecured notes due 2034 (the "Notes"). The issue price of the Notes is 100.000%. The offering is expected to close on February 12, 2026, subject to the satisfaction of customary closing conditions.</description>
</item>
<item>
<title>BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility</title>
<link>https://6ix.com/company/biomarin-pharmaceutical-inc/news/biomarin-announces-proposed-private-offering-senior-notes-and-syndication-new-senior</link>
<guid isPermaLink="true">https://6ix.com/company/biomarin-pharmaceutical-inc/news/biomarin-announces-proposed-private-offering-senior-notes-and-syndication-new-senior</guid>
<pubDate>Mon, 26 Jan 2026 05:00:00 GMT</pubDate>
<description>SAN RAFAEL, Calif., Jan. 26, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it intends to offer, subject</description>
</item>
<item>
<title>BioMarin Appoints Arpit Davé Chief Digital and Information Officer</title>
<link>https://6ix.com/company/biomarin-pharmaceutical-inc/news/biomarin-appoints-arpit-dav-chief-210500599</link>
<guid isPermaLink="true">https://6ix.com/company/biomarin-pharmaceutical-inc/news/biomarin-appoints-arpit-dav-chief-210500599</guid>
<pubDate>Mon, 12 Jan 2026 21:05:00 GMT</pubDate>
<description>BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced it has appointed Arpit Davé as Executive Vice President, Chief Digital and Information Officer, a new position reporting directly to President and Chief Executive Officer Alexander Hardy. Mr. Davé will be responsible for reimagining and executing BioMarin's enterprise technology strategy, data science and digital transformation to help create value for patients, employees and shareholders. He joins BioMarin today and will serve on the B</description>
</item>
<item>
<title>BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA</title>
<link>https://6ix.com/company/biomarin-pharmaceutical-inc/news/biomarin-present-44th-annual-jp-morgan-healthcare-conference-monday-january-12-11-15</link>
<guid isPermaLink="true">https://6ix.com/company/biomarin-pharmaceutical-inc/news/biomarin-present-44th-annual-jp-morgan-healthcare-conference-monday-january-12-11-15</guid>
<pubDate>Thu, 08 Jan 2026 05:00:00 GMT</pubDate>
<description>SAN RAFAEL, Calif., Jan. 8, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief</description>
</item>
<item>
<title>Veeva and BioMarin Form Long-Term Strategic Partnership</title>
<link>https://6ix.com/company/biomarin-pharmaceutical-inc/news/veeva-and-biomarin-form-long-term-strategic-partnership</link>
<guid isPermaLink="true">https://6ix.com/company/biomarin-pharmaceutical-inc/news/veeva-and-biomarin-form-long-term-strategic-partnership</guid>
<pubDate>Thu, 08 Jan 2026 05:00:00 GMT</pubDate>
<description>Partnership to help BioMarin increase speed and efficiency in developing and commercializing innovative therapiesPLEASANTON, Calif., and SAN RAFAEL, Calif.,</description>
</item>
<item>
<title>BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook</title>
<link>https://6ix.com/company/biomarin-pharmaceutical-inc/news/biomarin-acquire-amicus-therapeutics-4-124500714</link>
<guid isPermaLink="true">https://6ix.com/company/biomarin-pharmaceutical-inc/news/biomarin-acquire-amicus-therapeutics-4-124500714</guid>
<pubDate>Fri, 19 Dec 2025 12:45:00 GMT</pubDate>
<description>BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Amicus Therapeutics (Nasdaq: FOLD) announced today that BioMarin has entered into a definitive agreement to acquire Amicus for $14.50 per share in an all-cash transaction for a total equity value of approximately $4.8 billion. The agreement has been unanimously approved by the Boards of Directors of both companies and Amicus' Board of Directors unanimously recommended that Amicus' stockholders vote to adopt the agreement. The transaction is expecte</description>
</item>
<item>
<title>BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England</title>
<link>https://6ix.com/company/biomarin-pharmaceutical-inc/news/biomarin-participate-jefferies-global-healthcare-conference-tuesday-november-18-2025</link>
<guid isPermaLink="true">https://6ix.com/company/biomarin-pharmaceutical-inc/news/biomarin-participate-jefferies-global-healthcare-conference-tuesday-november-18-2025</guid>
<pubDate>Tue, 11 Nov 2025 05:00:00 GMT</pubDate>
<description>SAN RAFAEL, Calif., Nov. 11, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at the Jefferies</description>
</item>
<item>
<title>FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria</title>
<link>https://6ix.com/company/biomarin-pharmaceutical-inc/news/fda-accepts-biomarins-palynziqr-pegvaliase-pqpz-supplemental-biologics-license</link>
<guid isPermaLink="true">https://6ix.com/company/biomarin-pharmaceutical-inc/news/fda-accepts-biomarins-palynziqr-pegvaliase-pqpz-supplemental-biologics-license</guid>
<pubDate>Wed, 29 Oct 2025 04:00:00 GMT</pubDate>
<description>Application based on positive results from Phase 3 PEGASUS study, which demonstrated statistically significant blood phenylalanine (Phe) lowering compared to</description>
</item>
</channel>
</rss>